Integer Holdings Corporation (ITGR) stock plummeted 5.01% during Friday's trading session, as the medical device company faced macroeconomic headwinds and uncertainty surrounding tariffs that weighed on its fourth-quarter performance.

The company reported adjusted earnings per share of $1.43 for Q4 2024, missing analysts' estimates by 2.1%. While revenues grew 11.1% year-over-year to $449.5 million, slightly beating expectations, Integer's gross margin contracted by 110 basis points to 25.9%, raising concerns about profitability.

Oppenheimer downgraded its rating on Integer stock from "Outperform" to "Perform", citing uncertainty around potential tariff-induced structural dislocations and the stock reaching its price target. The firm stated it is "adopting a wait and see stance" on Integer, despite the company's exposure to high-growth MedTech segments.